Brett Dabruzzo
Overview
Explore the profile of Brett Dabruzzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Neurology
. 2025 Feb;
102(7_supplement_1):3371.
PMID: 39977883
Objective: To collect real-world data to evaluate the effectiveness, safety, and tolerability of adding atogepant to onabotulinumtoxinA as combination preventive treatment for chronic migraine (CM). Background: Combination use of atogepant...
2.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Pain Ther
. 2024 Dec;
14(1):441-444.
PMID: 39718742
No abstract available.
3.
Lipton R, Gandhi P, Tassorelli C, Reuter U, Harriott A, Holle-Lee D, et al.
Neurology
. 2024 Dec;
104(2):e210212.
PMID: 39715475
Background And Objectives: Three phase 3 trials demonstrated the efficacy and safety of atogepant in episodic migraine (EM) and chronic migraine (CM) across 12-week treatment periods. This analysis evaluates improvements...
4.
Peterlin B, Bond D, Ailani J, Dodick D, Liu Y, De Abreu Ferreira R, et al.
Cephalalgia
. 2024 Dec;
44(12):3331024241299753.
PMID: 39648629
Background: Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment. Methods: Five atogepant clinical trials in adults with migraine (one phase...
5.
Blumenfeld A, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, et al.
Pain Ther
. 2024 Sep;
13(6):1571-1587.
PMID: 39287781
Introduction: Combination use of atogepant and onabotulinumtoxinA has the potential to be more effective than either alone for the preventive treatment of chronic migraine (CM) due to their complementary mechanisms...
6.
Melo-Carrillo A, Strassman A, Malcolm K, Manack Adams A, Dabruzzo B, Briode R, et al.
Cephalalgia
. 2024 Sep;
44(9):3331024241278919.
PMID: 39252510
Background: OnabotulinumtoxinA (onabotA), is assumed to achieve its therapeutic effect in migraine through blocking activation of unmyelinated meningeal nociceptors and their downstream communications with central dura-sensitive trigeminovascular neurons in the...
7.
Ailani J, Gandhi P, Lalla A, Halker Singh R, McAllister P, Smith J, et al.
Headache
. 2024 Sep;
64(10):1253-1263.
PMID: 39248007
Objective: To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of episodic migraine (EM) in the United...
8.
Goadsby P, Friedman D, Holle-Lee D, Demarquay G, Ashina S, Sakai F, et al.
Neurology
. 2024 Jun;
103(2):e209584.
PMID: 38924724
Background And Objectives: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. We evaluated the efficacy of atogepant for the preventive treatment of...
9.
Lipton R, Nahas S, Pozo-Rosich P, Bilchik T, McAllister P, Finnegan M, et al.
J Headache Pain
. 2024 May;
25(1):83.
PMID: 38773375
Background: Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses evaluated the proportions of clinical trial participants who experienced...
10.
Buse D, Sakai F, Matharu M, Reed M, Fanning K, Dabruzzo B, et al.
Headache
. 2024 May;
64(5):469-481.
PMID: 38706199
Objective: To analyze data from the Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study in order to characterize preventive medication use and identify preventive usage gaps among people with migraine across...